Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasm Metastasis 1Graft vs Host Disease 1Bronchiolitis Obliterans Syndrome 1

Interventions

Methotrexate 6ruxolitinib 4ibrutinib 4Mycophenolic Acid 3Cyclosporine 3Transplantation Conditioning 2Tacrolimus 2Sirolimus 2Prednisone 2Methylprednisolone 2Cyclophosphamide 2Calcineurin Inhibitors 2thymoglobulin 1siplizumab 1remestemcel-l 1milatuzumab 1itacitinib 1eritoran 1axatilimab 1angiotensin I (1-7) 1Saline Solution 1Rituximab 1Radiotherapy 1Proto-Oncogene Proteins c-raf 1Photopheresis 1Peripheral Blood Stem Cell Transplantation 1Pentostatin 1Panobinostat 1KRN 7000 1Infliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Graft vs Host Disease × axatilimab × Clear all
NCT04710576 2026-03-16

AGAVE-201

Syndax Pharmaceuticals

Phase 2 Active not recruiting
241 enrolled 11 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡